

CORRIGENDUM

DOI: 10.3892/or.2018.6802

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models

RONALD A. LUBET, VERNON E. STEELE, M.M. JULIANA, ANN BODE, FARIBA MOEINPOUR and CLINTON J. GRUBBS

Oncol Rep 40: 1545-1553, 2018; DOI: 10.3892/or.2018.6313

The AKT inhibitor employed in this article was identified as MK 2206 (8-[4-(1-aminocyclobutyl) phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one hydrochloride (1:2). However, another AKT inhibitor was actually used, which is typically identified as Akt I-1,2 (HC.I. IPA (2-[4-(3-phenylquinoxalin-2-yl)phenyl]propan-2-amine hydrochloride isopropanol (1:1:1). Therefore, all references to MK 2206 in the paper should have been made to Akt I-1.2. Based on the experience of the present authors with a range of targeted inhibitors, it is expected that both inhibitors would have given rise to similar results; therefore, the results obtained in the paper are not likely to have been greatly affected as a consequence of the use of the alternative inhibitor.

The authors regret that this error was not identified sooner, prior to the publication of the article, and regret any inconvenience that has been caused.



This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.